Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils.

Autor: Buchheit KM; Division of Allergy and Clinical Immunology, AERD Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Shaw D; Department of Respiratory Medicine and Thoracic Surgery, Institute for Lung Health, Glenfield Hospital, Leicester, UK., Chupp G; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA., Lehtimaki L; Faculty of Medicine and Health Technology, Allergy Centre, Tampere University Hospital, Tampere University, Tampere, Finland., Heffler E; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Personalized Medicine, Asthma and Allergy Clinic, IRCCS Humanitas Research Hospital, Milan, Italy., Finney-Hayward T; Global Medical Affairs, Respiratory Specialty Care, GSK, London, UK., Zangrilli J; Clinical Science, GSK, Collegeville, Pennsylvania, USA., Kwiatek J; US Medical Affairs, GSK, Collegeville, Pennsylvania, USA., Siddiqui S; National Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College London, London, UK., Roufosse F; Department of Internal Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium., Thamboo A; Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada., West N; School of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, Australia., Vichiendilokkul A; Clinical Science, GSK, Collegeville, Pennsylvania, USA., Hellings PW; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.; Upper Airways Disease Research Unit, University of Ghent, Ghent, Belgium., Peters A; Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Howarth PH; Global Medical Affairs, Respiratory Specialty Care, GSK, London, UK.
Jazyk: angličtina
Zdroj: Allergy [Allergy] 2024 Oct; Vol. 79 (10), pp. 2662-2679.
DOI: 10.1111/all.16303
Abstrakt: Interleukin (IL)-5 is the key cytokine in the maturation, activation, proliferation, migration and survival of eosinophils, which are key effector cells in many upper and lower airway diseases. Through its effects on eosinophils, IL-5 indirectly contributes to various pathophysiological processes including tissue damage, repair and remodelling. Understanding the importance of IL-5 in eosinophil-associated diseases led to the development of anti-IL-5 therapies, which provide clinical benefits across a range of conditions. However, recent evidence suggests that eosinophil-depletion alone may not account for all of the therapeutic effects of anti-IL-5 therapy and that IL-5 may also contribute to disease independently of its effects on eosinophils. Indeed, evidence from ex vivo studies and targeted therapy in vivo demonstrates that IL-5 and its inhibition affects a much broader range of cells beyond eosinophils, including epithelial cells, plasma cells, mast cells, basophils, neutrophils, type 2 innate lymphoid cells, T regulatory cells and fibroblasts. This review will provide an update on the evidence supporting the breadth of IL-5 biology relevant to disease pathogenesis beyond eosinophil-associated inflammation, where there is a need for additional insight, and the clinical implications of a more central role of IL-5 in type 2 inflammation.
(© 2024 GSK and The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: